|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0205210,
umls-concept:C0205390,
umls-concept:C0406317,
umls-concept:C0439661,
umls-concept:C0522503,
umls-concept:C0596545,
umls-concept:C1174995,
umls-concept:C1274040,
umls-concept:C1320125,
umls-concept:C1512888
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-6-23
|
|
pubmed:abstractText |
Efalizumab (anti-CD11a), a humanized monoclonal antibody, blocks multiple T-cell-dependent functions implicated in the pathogenesis of psoriasis, including T-cell activation, migration to the skin, reactivation in psoriatic skin and interactions with keratinocytes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-0963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
155
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
170-81
|
|
pubmed:meshHeading |
pubmed-meshheading:16792770-Adult,
pubmed-meshheading:16792770-Analysis of Variance,
pubmed-meshheading:16792770-Antibodies, Monoclonal,
pubmed-meshheading:16792770-Double-Blind Method,
pubmed-meshheading:16792770-Female,
pubmed-meshheading:16792770-Humans,
pubmed-meshheading:16792770-Immunosuppressive Agents,
pubmed-meshheading:16792770-Logistic Models,
pubmed-meshheading:16792770-Male,
pubmed-meshheading:16792770-Middle Aged,
pubmed-meshheading:16792770-Psoriasis,
pubmed-meshheading:16792770-Severity of Illness Index,
pubmed-meshheading:16792770-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
|
|
pubmed:affiliation |
Hôpital Saint Louis, Paris, France, and University Hospital Charite, Berlin, Germany. louis.dubertret@free.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
